The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients

NCT02338128 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2019-07-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether Febuxostat could protect cardiovascular function of peritoneal dialysis patients by lowering serum uric acid.

Conditions

  • Disorders Associated With Peritoneal Dialysis
  • Hyperuricemia

Sponsors & Collaborators

  • Shanghai 10th People's Hospital

    lead OTHER

Principal Investigators

  • Ling Wang, MD, PhD · Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02338128 on ClinicalTrials.gov